Research accomplishments of this project include: 1) This project allows us to study the largest cohort of patients with ALPS, one of the first genetic disorders of immunedysregulation. ALPS natural history study based on follow up of these patients over 18 yeas has been completed and a manuscript is being generated summarizing the critical features of the clinical and molecular pathogenesis in 150 patients with ALPS-FAS with a median followup of 13 years. This included the validation of new biomarkers as well as establishing new modes of treatment for the disorder. It elucidates the role of fas mediated apoptosis in lymphocyte homeostasis and lymphoma genesis. 2)This project has also led to identifying new genetic causes of ALPS like disorders by identification of mutations affecting RAS pathway in 14 patients, otherwise known as Ras Associated Leukoproliferative Disorder (RALD) : RALD: Patients with this ALPS like syndrome caused by somatic mutations in NRAS and KRAS are currently classified separately as ALPS related apoptosis disorders. These patients with somatic NRAS and KRAS mutations present with autoimmune phenomena, massive splenomegaly, modest lymphadenopathy and normal or only marginally elevated TCR alpha/beta+ DNT cells. Their lymph node histopathology is also not typical of ALPS-FAS. Additionally, these patients show abnormalities of the myeloid compartment, with chronic persistent monocytosis, mimicking juvenile myelomonocytic leukemia (JMML) in otherwise asymptomatic young patients. 3) Provided below is the current classification scheme that we have devised for ALPS patients based on the particular molecular defect present: ALPS-FAS : mutations in the TNFRSF6 (tumor necrosis factor receptor superfamily 6) gene, encodes the protein CD95 (Fas). ALPS-sFas: somatic mutant: TNFRSF6 gene defect in the double negative T (DNT) cell population. ALPS-FASLG: mutations in TNFSF6 gene, encodes the protein CD95 ligand (Fas ligand). ALPS-CASP10: mutations in CASP10 gene, encodes caspase-10. ALPS-U: associated mutation unidentified to date. 4) Recently we clarified that the cause of disordered FAS protein function leading to ALPS is based on haploinsuffiiciency caused by mutations affecting the extracellular portion of the protein in some patients. This is a newly emerging unique mechanism of genetic dysfunction. With support from NCBI we have implemented a web based publication of the existing databases of pathogenic FAS mutations, by far the commonest cause of ALPS, which is publicly available and can be used for diagnostic help by referring to NCBI NIH ALPS website <www.ncbi.nlm.nih.gov/lovd/home.php?select_db=FAS>. 5) Characterized the pathophysiology and clinical phenotype of the second largest subgroup of ALPS patients in our cohort with somatic mutations in the FAS gene mostly limited to their ALPS signature cells, also known as double negative T lymphocytes. 6) Extended the use of PET scans as an imaging modality in patients with ALPS associated lymphadenopathy as a tool to monitor patients with suspected ALPS associated cancer of the lymphoid system (lymphoma). We have identified lymphomas associated with ALPS-FAS in approximately 10% of our patients. Ongoing critical surveillance for lymphoma and its early diagnosis and treatment has been pursued over the last 20 years of longitudinal follow up of these patients. 7) Continued search for new genetic mutations in the subgroup of patients with ALPS and undetermined genetic defects using emerging genomic and cell biology tools. Currently a large group of patients with unknown molecular etiologies are being subjected to whole exome DNA sequencing and analysis. 8) More recently the ALPS Clinical group is being repositioned to tackle new classes of immunological disorders which has involved the recruitment of new members of the team as well as special inservices on genetics and molecular biology for the nursing and ancillary support staff. 9) Continued efforts to streamline the techniques of apoptosis assay by evaluating Fas mediated cell death in lymphocyte subsets so that this test procedure can be readily adapted in more clinical laboratories for patient evaluation. 10) Confounding factors in the clinical presentation of ALPS and another hematological condition called HLH (Hemophagocytic lymphohistiocytosis) have been identified and clinicians are being advised to be aware of the distinguishing biomarkers in both conditions.

Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
2013
Total Cost
$477,005
Indirect Cost
City
State
Country
Zip Code
Shah, Shaili; Wu, Eveline; Rao, V Koneti et al. (2014) Autoimmune lymphoproliferative syndrome: an update and review of the literature. Curr Allergy Asthma Rep 14:462
Price, Susan; Shaw, Pamela A; Seitz, Amy et al. (2014) Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood 123:1989-99
Lucas, Carrie L; Kuehn, Hye Sun; Zhao, Fang et al. (2014) Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110ýý result in T cell senescence and human immunodeficiency. Nat Immunol 15:88-97
Lo, Bernice; Ramaswamy, Madhu; Davis, Joie et al. (2013) A rapid ex vivo clinical diagnostic assay for fas receptor-induced T lymphocyte apoptosis. J Clin Immunol 33:479-88
Hansford, Jordan R; Pal, Manika; Poplawski, Nicola et al. (2013) In utero and early postnatal presentation of autoimmune lymphoproliferative syndrome in a family with a novel FAS mutation. Haematologica 98:e38-9
Rao, V Koneti (2013) ITP: hematology's Cosette from Les Miserables. Blood 121:1928-30
Langan, Russell C; Gill, Fred; Raiji, Manish T et al. (2013) Autoimmune pancreatitis in the autoimmune lymphoproliferative syndrome (ALPS): a sheep in wolves' clothing? Pancreas 42:363-6
Rao, V Koneti; Price, Susan; Perkins, Katie et al. (2009) Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS). Pediatr Blood Cancer 52:847-52
Dowdell, Kennichi C; Pesnicak, Lesley; Hoffmann, Victoria et al. (2009) Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, diminishes lymphoproliferation in the Fas -deficient MRL/lpr(-/-) murine model of autoimmune lymphoproliferative syndrome (ALPS). Exp Hematol 37:487-94